Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe
Luca Moscetti(Ospedale di Belcolle), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Claudia Omarini(University of Modena and Reggio Emilia), Angela Toss(University of Modena and Reggio Emilia), Cecilia Nasso(University of Modena and Reggio Emilia), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Isabella Sperduti(San Gallicano Hospital), Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Massimo Dominici(University of Modena and Reggio Emilia)
Cited by 10
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339
Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells
|Blood|2010|265